Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A4JK
|
|||
| Former ID |
DAP000667
|
|||
| Drug Name |
Butabarbital
|
|||
| Synonyms |
Butabarb; Butabarbitone; Butalan; Butatab; Butatal; Buticaps; Butisol; Butrate; Medarsed; Nilox; Sarisol; Secbubarbital; Secbutabarbital; Secbutabarbitale; Secbutabarbitalum; Secbutobarbital; Secbutobarbitone; Unicelles; Butabarbital [USAN]; Butisol sodium; Secbutabarbital [INN]; Secbutabarbitale [DCIT]; Sodium butabarbital;Butabarbital (USP); Butabarbital (VAN); Butisol (TN); Sec-Butobarbitone; Secbutabarbitalum [INN-Latin]; 5-(butan-2-yl)-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylpropyl)barbiturate; 5-Ethyl-5-(1-methylpropyl)barbituric acid; 5-Ethyl-5-isobutylbarbituric acid; 5-SEC-BUTYL-5-ETHYL-BARBITURIC ACID; 5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(1-methylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-sec-Butyl-5-ethylbarbituric acid; 5-sec-Butyl-5-ethylmalonyl urea; 5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Insomnia [ICD-11: 7A00-7A0Z] | Approved | [1], [2] | |
| Therapeutic Class |
Antianxiety Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H16N2O3
|
|||
| Canonical SMILES |
CCC(C)C1(C(=O)NC(=O)NC1=O)CC
|
|||
| InChI |
1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
|
|||
| InChIKey |
ZRIHAIZYIMGOAB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 125-40-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10029, 87956, 4652646, 8145874, 8151655, 10506081, 14822479, 17397334, 29221643, 46505051, 48415669, 49873886, 49874286, 57321344, 78596856, 92714693, 103165895, 104300710, 125823081, 126623947, 126677092, 129943999, 134337956, 134975727, 135058578, 137006035, 137213136, 152101627, 160963585, 164837420, 178103713, 179225562, 198993278, 223656882, 226458418, 249521873, 250021615
|
|||
| ChEBI ID |
CHEBI:3228
|
|||
| ADReCS Drug ID | BADD_D00319 ; BADD_D00320 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor alpha-1 (GABRA1) | Target Info | Antagonist | [3], [4], [5] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Iron uptake and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7137). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 085550. | |||
| REF 3 | DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. | |||
| REF 4 | Hypnotic drugs. Med Lett Drugs Ther. 2000 Aug 7;42(1084):71-2. | |||
| REF 5 | Effect of barbiturates on polyphosphoinositide biosynthesis and protein kinase C activity in synaptosomes. Neuropharmacology. 1989 Dec;28(12):1317-23. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.